Research Use Only - Not for human consumption. 18+ only.

TB-500 vs PEG-MGF

Evidence-based comparison · Updated 2026

Summary

TB-500 and PEG-MGF serve different primary functions: TB-500 targets broad tissue repair, inflammation reduction, and angiogenesis across multiple tissue types, while PEG-MGF focuses specifically on muscle satellite cell activation and muscle fiber recovery. Researchers studying connective tissue, wound healing, or cardiovascular repair typically favor TB-500, while those investigating skeletal muscle growth and post-training recovery lean toward PEG-MGF. Both carry a Grade C evidence rating and are research-use only.

Side-by-Side Comparison

TB-500PEG-MGF
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataCGrade CPrimarily animal or in-vitro studies; limited human data
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits
  • +Promotes tissue repair and regeneration
  • +Reduces inflammation throughout the body
  • +Improves flexibility and range of motion
  • +Supports cardiovascular health
  • +Enhances angiogenesis
  • +Promotes muscle fiber repair
  • +Enhances recovery from training
  • +May increase muscle growth
  • +Neuroprotective properties
  • +Improved endurance
Dosage2-2.5 mg mg — 2x/week (loading phase) then 1x/week (maintenance)200-400 mcg mcg — 2-3x weekly
RouteSubcutaneous, IntramuscularSubcutaneous
CategoryHealing & RecoveryHealing & Recovery

Full research page

TB-500 →

Full research page

PEG-MGF →

Which Should You Choose?

TB-500 acts through actin polymerization and broad growth factor modulation to repair diverse tissue types, whereas PEG-MGF operates via IGF-1 receptor signaling to selectively activate muscle satellite cells, with pegylation extending its systemic half-life beyond native MGF.

Choose TB-500 when:

  • +Research focus involves multi-tissue repair including tendon, ligament, skin, or cardiac tissue rather than muscle exclusively
  • +The study design requires anti-inflammatory effects alongside regenerative signaling across a wider biological scope
  • +Angiogenesis or vascular remodeling is a primary outcome of interest in the research model

Choose PEG-MGF when:

  • +The research question centers on skeletal muscle hypertrophy, satellite cell proliferation, or myogenic differentiation
  • +A longer systemic half-life is needed to allow sustained anabolic signaling without repeated local injections, which pegylation provides
  • +The model involves mechanical stress or resistance-type loading where IGF-1 Ec pathway activation is the target mechanism

Combining TB-500 and PEG-MGF has been explored in some research contexts because their mechanisms are complementary, with TB-500 addressing connective tissue and inflammatory components while PEG-MGF drives muscle-specific regeneration, though no controlled clinical data currently validates the safety or efficacy of this combination.

Frequently Asked Questions

Do TB-500 and PEG-MGF work through overlapping mechanisms, or are their pathways distinct enough to justify combining them?⌄
Their primary mechanisms are largely distinct. TB-500 acts through thymosin beta-4-mediated actin sequestration and broad growth factor modulation affecting multiple tissue types, while PEG-MGF signals through the IGF-1 receptor to activate muscle satellite cells specifically. This mechanistic separation is the basis for researchers considering them complementary rather than redundant, though shared downstream effects on cell proliferation mean some overlap exists.
How do the recovery timelines differ when using TB-500 versus PEG-MGF in injury research models?⌄
TB-500 research suggests its tissue repair and anti-inflammatory effects may begin to manifest over days to weeks, depending on injury type and dosing frequency, with effects observed across connective and vascular tissues. PEG-MGF, due to its extended half-life from pegylation, is thought to provide more sustained anabolic signaling after a single administration compared to non-pegylated MGF, potentially accelerating muscle-specific recovery within a similar window. Direct head-to-head timeline data from controlled studies remains limited.
If a research model involves both muscle damage and connective tissue injury, which peptide would be the more appropriate single choice?⌄
TB-500 is generally considered the broader-spectrum option in this scenario, given its documented activity across muscle, tendon, ligament, and vascular tissue repair pathways. PEG-MGF would address the muscle component more potently through IGF-1 receptor activation but lacks the connective tissue and anti-inflammatory coverage that TB-500 provides. For mixed-injury models, TB-500 as a monotherapy covers more biological targets, though some researchers use both for complementary coverage.
Are the dosing and administration protocols for TB-500 and PEG-MGF similar, and does this affect how they might be combined in research?⌄
The two peptides differ in typical administration frequency. TB-500 is often administered on a loading and maintenance schedule due to its moderate half-life and systemic distribution needs, whereas PEG-MGF's pegylation extends its half-life significantly, allowing less frequent dosing compared to native MGF. When combined in research settings, this difference means protocols must be designed independently for each compound rather than using a unified schedule, which adds complexity to study design and confounds direct attribution of observed effects.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin